| ZymoGenetics, Inc. Q1 2010 Earnings Call Transcript ZymoGenetics, Inc. (ZGEN)Q1 2010 Earnings CallMay 4, 2010 4:30 pm ETComplete Story » seekingalpha.com |
Biogen Names Scangos as CEO Biogen Idec named George Scangos as chief executive, hiring him away from the same role at smaller drug developer Exelixis. online.wsj.com |
Happy Couples, Go Ahead and Fight Couples fight. The good news: If you fight the right way it can actually make your relationship happier and healthier. online.wsj.com |
Arena Pharmaceutical's Lorqess: A Briefing Document Analysis Rockford Coscia submits:I’d like to think that my specialty is collecting and interpreting data on biotech stocks. In the case of Arena Pharmaceuticals (ARNA), the data is collected and largely interpreted – all with a nice little bow on it. So rather than try to provide a thorough and unbiased analysis – which would be nearly impossible given the mountain of data – I will just insist that you read it for yourself. If you’re making a play on this stock, long or short, you have to do this due diligence. Instead I’ll provide a few selected comments and describe how I think this will go and how I intend to play it. Gekkowire has provided an excellent analysis, given the difficulties, and I suggest you give that a look here.Complete Story » seekingalpha.com |
China Cord Blood Corporation Updates Status Regarding Share Repurchase Program [PR Newswire] - China Cord Blood Corporation , the first and largest cord blood bank operator in China, today announced that since the authorization of the stock repurchase program on September 15, 2010, the Company has repurchased approximately 309,000 ordinary shares for approximately US$1.6 million through October 6, 2010 at an average price per share of US$5.32. Â This amount represents approximately 10.7% of the total repurchase program authorized by CCBC's Board of Directors, with approximately US$13.4 million remaining in the Company's buyback authorization for repurchase prior to September 2011. us.rd.yahoo.com |